ArticleOncoTargets and therapy2019
NCAPG Promotes The Proliferation Of Hepatocellular Carcinoma Through PI3K/AKT Signaling.
Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.
- NCAPG as a novel prognostic biomarker in numerous cancers: a meta-analysis and bioinformatics analysis.Aging · 2023Pooled it
- Calcineurin Homologous Protein 2 Acts as a Conditional Modulator of Migration and Proliferation in Human Bone Sarcoma Cells.Cancers · 2026Article
- The Role of Deubiquitinating Enzymes in Primary Bone Cancer.Molecular biotechnology · 2025Review
- Chlorogenic acid attenuates oxidative damage in rat lacrimal gland epithelial cells via PI3K/AKT/FoxO3 signaling: network pharmacology and experimental evidence.Scientific reports · 2025Article
- Hepatocellular carcinoma: signaling pathways and therapeutic advances.Signal transduction and targeted therapy · 2025Review
- Integrative Bioinformatics Analysis for Targeting Hub Genes in Hepatocellular Carcinoma Treatment.Current genomics · 2025Article
- A Bioinformatics-Based Approach to Discover Novel Biomarkers in Hepatocellular Carcinoma.Iranian journal of public health · 2024Article
- Important role and underlying mechanism of non‑SMC condensin I complex subunit G in tumours (Review).Oncology reports · 2024Review
- Up-regulation of NCAPG mediated by E2F1 facilitates the progression of osteosarcoma through the Wnt/β-catenin signaling pathway.Translational cancer research · 2024Article
- miR-122-5p Promotes Cowshed Particulate Matter2.5-Induced Apoptosis in NR8383 by TargetingToxics · 2024Article
- Sorcin promotes proliferation of hepatocellular carcinoma by regulating VEGFA/B via PI3K pathway.Journal of physiology and biochemistry · 2024Article
- Knockdown of NCAPD3 inhibits the tumorigenesis of non-small cell lung cancer by regulation of the PI3K/Akt pathway.BMC cancer · 2024Article
- Hub gene identification and immune infiltration analysis in hepatocellular carcinoma: Computational approach.In silico pharmacology · 2024Article
- Role and mechanism ofFrontiers in pharmacology · 2024Article
- Association ofFrontiers in veterinary science · 2024Article
- Nonstructural maintenance of chromatin condensin I complex subunit G promotes the progression of glioblastoma by facilitating Poly (ADP-ribose) polymerase 1-mediated E2F1 transactivation.Neuro-oncology · 2023Article
- NCAPG stimulates lung adenocarcinoma cell stemness through aerobic glycolysis.The clinical respiratory journal · 2023Article
- Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma.Pharmaceutics · 2023Review
- GBAP1 functions as a tumor promotor in hepatocellular carcinoma via the PI3K/AKT pathway.BMC cancer · 2023Article
- Association of NCAP family genes with prognosis and immune infiltration of human sarcoma.Aging · 2023Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeStudies show that high expression of non-SMC condensin I complex subunit G (NCAPG) is associated with many tumors. In this study, we explore the mechanism by which NCAPG promotes proliferation in hepatocellular carcinoma (HCC). PATIENTS AND
methodsLiver cancer and paracancerous tissue specimens of 90 HCC patients were collected, and expression levels of NCAPG in these tissues and cell lines were evaluated by Western blotting and immunohistochemistry. HCC cells were transfected with siRNAs and plasmids, and pathway activators or inhibitors were added. The 5-ethynyl-2'-deoxyuridine (EdU) proliferation assay was used to measure cell proliferation. Flow cytometry was used to evaluate cell apoptosis. Western blot assays were performed as a standard procedure to detect total protein expression. Treated HCC cells were subcutaneously injected into nude mice.
resultsAnalysis using the Oncomine database showed that NCAPG was upregulated in HCC and immunohistochemistry and Western blot assays showed it was upregulated in both HCC tissues and HCC cell lines. The overexpression of NCAPG could promote HCC cell proliferation and reduce HCC cell apoptosis. More importantly, RNA-sequencing analysis predicted that NCAPG plays a role in the HCC via PI3K-AKT signaling pathway. The PI3K/AKT/FOXO4 pathway was aberrantly activated, and the expressions of apoptosis-related protein were altered when NCAPG was overexpressed or silenced both in vitro and in vivo. LY294002, a PI3K inhibitor, could eliminate the NCAPG role of promoting HCC cell proliferation and reducing HCC cell apoptosis, while 740Y-P, a PI3K activator, contributed to the opposite effect.
conclusionNCAPG functions as an oncogene in HCC and plays a role in promoting cell proliferation and antiapoptosis through activating the PI3K/AKT/FOXO4 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.